-
LGK-974 Beyond Oncology: PORCN Inhibition in Bone
2026-09-24
LGK-974 is a potent PORCN inhibitor with applications that extend beyond Wnt-dependent cancer models. This article examines a 2025 sclerosteosis study and explains how its skeletal findings can guide pathway selection, target-engagement measurements, and interpretation of preclinical experiments.
-
Berberrubine and Selective IMPDH2 Inhibition in CRC
2026-09-23
The reference study identifies berberrubine as a selective, competitive IMPDH2 inhibitor that restricts guanine nucleotide production and suppresses colorectal cancer growth. Its combination of structure-based screening, target-engagement assays, guanosine rescue, and validation in two mouse models provides a strong framework for mechanism-led colorectal cancer research, while leaving important translational questions unresolved.
-
PNU 74654 for Wnt Signaling Pathway Studies
2026-09-22
PNU 74654 provides a soluble-in-DMSO pharmacological handle for timing-sensitive Wnt/β-catenin experiments in cancer, stem cell, and differentiation models. This guide pairs practical dosing, controls, and troubleshooting with a careful interpretation of the reference study, where GSK3 inhibition activated rather than blocked β-catenin signaling.
-
Tunable Human Intestinal Organoids for Cell-Fate Control
2026-09-22
The reference study establishes a human small intestinal organoid system that maintains strong proliferation while expanding epithelial cell diversity under a single culture condition. By combining stemness-enhancing pathway modulation with targeted control of Wnt, Notch, BMP, and BET-dependent signals, the work makes self-renewal and differentiation more reversibly tunable for organoid research.
-
YBX1–SHANK3 Methylation in Schizophrenia
2026-09-21
The reference study identifies a methylation-dependent regulatory relationship between YBX1 and SHANK3 that links peripheral blood findings with developing cortical interneurons in schizophrenia. Its combination of PBMC methylation profiling, imaging and symptom correlations, and cell-type-specific validation supports SHANK3 promoter hypermethylation as a candidate peripheral biomarker and a mechanistic clue to neurodevelopmental pathology.
-
NAD+ at the Redox–Stress Response Interface
2026-09-21
Explore how Nicotinamide Adenine Dinucleotide (NAD+) connects redox metabolism with PARP1 signaling, autophagy, and non-apoptotic caspase activity. This mechanistic guide translates recent breast cancer findings into better NAD+ assay design and interpretation.
-
Hexa His Tag Peptide: Cleaner IP Design
2026-09-20
Learn how the Hexa His tag peptide enables antibody-compatible elution of His-tagged proteins while minimizing antibody-chain carryover. This guide connects competitive elution strategy with insights from AptaBLE, a deep-learning platform for protein–aptamer interaction analysis.
-
RIPA Lysis Buffer Strong: Workflow and Troubleshooting
2026-09-19
RIPA Lysis Buffer Strong combines high detergent strength with inhibitor-free customization for protein extraction from animal cells and tissues. This guide explains how to optimize sample handling for Western blotting, immunoprecipitation, ELISA, and kinase-focused workflows while avoiding common compatibility problems.
-
6C Culture Extends Mouse Corneal Epithelial Growth
2026-09-19
An et al. developed a serum-free, feeder-free 6C culture system that combines six signaling modulators with keratinocyte-supportive calcium to preserve mouse corneal epithelial cell proliferative activity. The study links improved expansion and wound repair with reduced epithelial–mesenchymal transition, providing a practical platform for corneal epithelial biology and regenerative medicine research.
-
Indometacin, COX-2, and Pancreatic Stellate Cells
2026-09-18
The reference study identifies COX-2 as a pharmacologically relevant link between human pancreatic stellate cell activation and the desmoplastic environment of pancreatic ductal adenocarcinoma. Using viability, migration, gene-expression, protein, and immunofluorescence analyses, it shows that indometacin suppresses stellate-cell activity while reducing COX-2 and α-SMA expression.
-
Indomethacin: Practical Research Workflow
2026-09-17
Indomethacin is a nonsteroidal anti-inflammatory drug for controlled cyclooxygenase perturbation and exploratory studies of inflammation, lipid metabolism, and membrane signaling. This guide covers solvent handling, assay controls, and interpretation boundaries; it should not be used as a substitute for a pathway-specific probe or model-matched literature evidence.
-
Directed hiPSC Differentiation into Corneal Endothelium
2026-09-17
Diao and colleagues developed a two-stage, chemically defined and serum-free method for converting human induced pluripotent stem cells into neural crest cells and then hCEC-like cells. The study links sequential TGF-β and Wnt pathway control with marker-defined lineage progression, providing a practical foundation for corneal endothelial cell research while leaving functional maturation and transplantation efficacy for further validation.
-
Carbapenemase Gene Transmission in CREC, Guangdong
2026-09-16
This study combines gene-localization analysis, antimicrobial susceptibility testing, conjugation experiments, and strain typing to clarify how carbapenemase-encoding genes circulate among carbapenem-resistant Enterobacter cloacae in Guangdong teaching hospitals. Its findings emphasize plasmid-associated blaNDM-1, extensive multidrug resistance, and the need to distinguish horizontal gene transfer from clonal dissemination in hospital surveillance.
-
IWP-L6: From Porcn Inhibition to Wnt Translation
2026-09-16
IWP-L6 offers a precise way to interrogate Porcupine-dependent Wnt ligand maturation across cellular, developmental, and organotypic models. This thought-leadership perspective connects upstream Wnt pathway control with the O-GlcNAcylation and glycolytic mechanisms implicated in bone formation, while defining the translational limits of current evidence.
-
Indometacin, COX-2, and Pancreatic Stellate Cells
2026-09-15
The reference study shows that indometacin suppresses human pancreatic stellate cell viability, migration, and myofibroblastic activation alongside reduced COX-2 expression. Its main contribution is to position COX-2 as a pharmacologically tractable regulator of the desmoplastic stromal compartment in pancreatic ductal adenocarcinoma, while also defining useful molecular and phenotypic assay combinations.